LCB02A / LigaChem Biosci - LARVOL DELTA

LCB02A, a Claudin 18.2-directed ADC, for the Treatment of Gastric, Pancreatic, and Other Claudin 18.2-Expressing Cancers (ESMO 2026) - No abstract available

ADC • Oncology • CLDN18

Phase 1/2 Trial of Claudin 18.2 (CLDN18.2)-Directed Antibody-Drug Conjugate LCB02A in Patients with CLDN18.2-positive Advanced Solid Tumors (ESMO 2026) - No abstract available

ADC • Clinical • Metastases • P1/2 data • Oncology • Solid Tumor • CLDN18

LigaChem Biosciences…Science will present its antibody-drug conjugate candidate (LCB02A). (Chosun Biz) - "LigaChem Biosciences plans to explain the path from preclinical to clinical entry....After confirming efficacy in the preclinical stage, the company will conduct a phase 1 trial in 191 cancer patients."

New P1 trial • Preclinical • Oncology

A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=191 | Recruiting | Sponsor: LigaChem Biosciences, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Oncology • Solid Tumor • CLDN18

LigaChem ADC Research Head Chung Chul-woong: “Four next-generation ADCs to enter Phase 1 this year” (BioNews) - "In particular, the gastric cancer-targeted ADC 'LCB02A (Claudin 18.2 ADC),' expected to be administered to its first patient in the third quarter of this year...'LCB97 received IND approval from the Japanese regulatory authorities as planned, and we are currently preparing for a global IND submission.'...'An IND submission for SOT106 is planned for H2 2026.'"

IND • Trial status • Gastric Cancer • Osteosarcoma • Sarcoma • Soft Tissue Sarcoma

LigaChem files IND for global phase 1/2 trial of ADC LCB02A (Korea Biomedical Review) - "The upcoming study is a multinational, multicenter clinical trial to be conducted at leading clinical institutions in the United States, Canada, and Korea. LCB02A previously signaled its entry into the clinical stage by receiving an official clinical trial number (NCT07460375) via ClinicalTrials.gov on March 10. LigaChem Bio aims to complete regulatory approval by the first half of this year, with a target to enroll the first patient by mid-2026." "

IND • Trial status • Solid Tumor

LCB02A an antibody drug conjugate (ADC) targeting CLDN18.2 expressing solid tumors (AACR 2024) - "Preliminary toxicity assessment in cynomolgus monkeys (CLDN18.2 cross-reactive species) demonstrated that LCB02A was well tolerated, with repeat doses of up to 60 mg/kg. In conclusion, LCB02A is a promising ADC for the treatment of CLDN18.2 expressing solid tumors including gastric cancer (GC) and pancreatic ductal adenocarcinoma (PDAC)."

ADC • Gastric Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • CLDN18

A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=191 | Not yet recruiting | Sponsor: LigaChem Biosciences, Inc.

First-in-human • New P1/2 trial • Oncology • Solid Tumor • CLDN18